{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:31:23Z","timestamp":1791102683766,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40261-022-01216-9","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:02:35Z","timestamp":1666551755000},"page":"1065-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mancaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Varriale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Boccellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-166X","authenticated-orcid":false,"given":"Antonio","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,23]]},"reference":[{"key":"1216_CR1","unstructured":"World health organization (WHO). https:\/\/covid19.who.int. Accessed 31 July 2022"},{"issue":"10223","key":"1216_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(20)30185-9.","journal-title":"Lancet"},{"key":"1216_CR3","unstructured":"World health organization (WHO). https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 31 July 2022."},{"issue":"13","key":"1216_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa2001316.","journal-title":"N Engl J Med"},{"issue":"6","key":"1216_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/jcm9061753","volume":"9","author":"J Baj","year":"2020","unstructured":"Baj J, Karaku\u0142a-Juchnowicz H, Teresi\u0144ski G, Buszewicz G, Ciesielka M, Sitarz R, et al. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020;9(6):1753. https:\/\/doi.org\/10.3390\/jcm9061753.","journal-title":"J Clin Med"},{"issue":"2","key":"1216_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/jmv.26427","volume":"93","author":"H Takagi","year":"2021","unstructured":"Takagi H. Risk and protective factors of SARS-CoV-2 infection. J Med Virol. 2021;93(2):649\u201351. https:\/\/doi.org\/10.1002\/jmv.26427.","journal-title":"J Med Virol"},{"issue":"9","key":"1216_CR7","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1093\/cid\/ciaa1012","volume":"72","author":"L Kim","year":"2021","unstructured":"Kim L, Garg S, O\u2019Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. 2021;72(9):e206\u201314. https:\/\/doi.org\/10.1093\/cid\/ciaa1012.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1216_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/jpm12060995","volume":"12","author":"MA Ortega","year":"2022","unstructured":"Ortega MA, Garc\u00eda-Montero C, Fraile-Martinez O, Colet P, Baizhaxynova A, Mukhtarova K, et al. Recapping the features of SARS-CoV-2 and its main variants: status and future paths. J Pers Med. 2022;12(6):995. https:\/\/doi.org\/10.3390\/jpm12060995.","journal-title":"J Pers Med."},{"issue":"1","key":"1216_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11845-021-02584-5","volume":"191","author":"A Vitiello","year":"2022","unstructured":"Vitiello A, Porta R, Pianesi L, Ferrara F. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. 2022;191(1):487\u20138. https:\/\/doi.org\/10.1007\/s11845-021-02584-5.","journal-title":"Ir J Med Sci"},{"key":"1216_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-022-02265-9","author":"A Vitiello","year":"2022","unstructured":"Vitiello A, La Porta R, Trama U, Ferrara F, Zovi A, Auti AM, et al. Pandemic COVID-19, an update of current status and new therapeutic strategies. Naunyn Schmiedebergs Arch Pharmacol. 2022. https:\/\/doi.org\/10.1007\/s00210-022-02265-9.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1216_CR11","unstructured":"Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine. Accessed 31 July 2022."},{"key":"1216_CR12","unstructured":"European Centre for Disease Prevention and Control. https:\/\/www.ecdc.europa.eu\/en\/news-events\/first-covid-19-vaccine-authorised-use-european-union. Accessed 31 July 2022."},{"key":"1216_CR13","unstructured":"European Medicines Agency. https:\/\/ec.europa.eu\/info\/live-work-travel-eu\/coronavirus-response\/safe-covid-19-vaccines-europeans_it. Accessed 31 July 2022."},{"key":"1216_CR14","unstructured":"Agenzia Italiana del Farmaco. https:\/\/www.aifa.gov.it\/web\/guest\/vaccini-covid-19. Accessed 31 July 2022."},{"issue":"3","key":"1216_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10787-021-00811-0","volume":"29","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F. Brief review of the mRNA vaccines COVID-19. Inflammopharmacology. 2021;29(3):645\u20139. https:\/\/doi.org\/10.1007\/s10787-021-00811-0.","journal-title":"Inflammopharmacology"},{"issue":"6","key":"1216_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.accpm.2020.10.006","volume":"39","author":"C Locht","year":"2020","unstructured":"Locht C. Vaccines against COVID-19. Anaesth Crit Care Pain Med. 2020;39(6):703\u20135. https:\/\/doi.org\/10.1016\/j.accpm.2020.10.006.","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"26","key":"1216_CR17","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.924700","volume":"5","author":"F Wang","year":"2020","unstructured":"Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit. 2020;5(26): e924700. https:\/\/doi.org\/10.12659\/MSM.924700.","journal-title":"Med Sci Monit"},{"key":"1216_CR18","unstructured":"EMA. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/comirnaty. Accessed 15 Sept 2022."},{"key":"1216_CR19","unstructured":"EMA. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria-previously-covid-19-vaccine-astrazeneca. Accessed 31 Dec 2021."},{"key":"1216_CR20","unstructured":"EMA. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax. Accessed 7 Oct 2022."},{"key":"1216_CR21","unstructured":"EMA. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jcovden-previously-covid-19-vaccine-janssen. Accessed 31 July 2022."},{"key":"1216_CR22","unstructured":"ECDC. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/data-covid-19-vaccination-eu-eea. Accessed 31 July 2022."},{"key":"1216_CR23","unstructured":"AIFA. https:\/\/www.aifa.gov.it\/documents\/20142\/1315190\/Rapporto_sorveglianza_vaccini_COVID-19_12.pdf. Accessed 31 July 2022."},{"issue":"2","key":"1216_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"1216_CR25","unstructured":"World health organization. Causality assessment of adverse event following immunization (AEFI): user manual for the revised WHO. classification. http:\/\/www.who.int\/vaccine_safety\/publications\/aevi_manual.pdf. Accessed 15 Sept 2022."},{"issue":"44","key":"1216_CR26","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","volume":"31","author":"AE Tozzi","year":"2013","unstructured":"Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013;31(44):5041\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.087.","journal-title":"Vaccine"},{"key":"1216_CR27","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/safety-covid-19-vaccines. Accessed 31 July 2022."},{"issue":"7","key":"1216_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939\u201349. https:\/\/doi.org\/10.1016\/S1473-3099(21)00224-3.","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"1216_CR29","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, mRNA-1273 Study Group, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2028436.","journal-title":"N Engl J Med"},{"issue":"5","key":"1216_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, COVE Study Group, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"issue":"1","key":"1216_CR31","doi-asserted-by":"publisher","first-page":"15510","DOI":"10.1038\/s41598-022-19936-5","volume":"12","author":"T Akaishi","year":"2022","unstructured":"Akaishi T, Onodera T, Takahashi T, Harigae H, Ishii T. Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan. Sci Rep. 2022;12(1):15510. https:\/\/doi.org\/10.1038\/s41598-022-19936-5.","journal-title":"Sci Rep"},{"key":"1216_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2022.2116008","volume":"24","author":"A Esmaeilzadeh","year":"2022","unstructured":"Esmaeilzadeh A, Maleki AJ, Moradi A, Siahmansouri A, Yavari MJ, Karami P, Elahi R. Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks. Expert Rev Vaccines. 2022;24:1\u201318. https:\/\/doi.org\/10.1080\/14760584.2022.2116008.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"1216_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/diagnostics11040579","volume":"11","author":"B Doroftei","year":"2021","unstructured":"Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021;11(4):579. https:\/\/doi.org\/10.3390\/diagnostics11040579.","journal-title":"Diagnostics (Basel)."},{"issue":"365","key":"1216_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2022.07.031","volume":"15","author":"A Simone","year":"2022","unstructured":"Simone A, Herald J, Chen A, Nayak R, Shen YA, Lee MS. Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults. Int J Cardiol. 2022;15(365):41\u20133. https:\/\/doi.org\/10.1016\/j.ijcard.2022.07.031 (Epub 2022 Jul 21).","journal-title":"Int J Cardiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01216-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T14:15:41Z","timestamp":1669731341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,23]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01216-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,23]]},"assertion":[{"value":"9 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"FF: conceptualization, writing\u2014original draft, methodology, supervision, validation. CM: supervision, validation. AV: conceptualization, writing\u2014original draft. SS: conceptualization, writing\u2014original draft. AZ: writing\u2014review and editing. EN: supervision, validation. UT: supervision, validation.\u00a0MB: supervision, validation. AV: writing\u2014review and editing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"No funding was received to conduct this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Full availability of data and materials. All stated data can be provided to the reader on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could appear to have influenced the work reported in this paper. The authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the Administrations to which they belong.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}